LightPath Technologies, Inc. (NASDAQ: LPTH) is a recognized leader in optical solutions for industrial, defense, communications, test and measurement, and medical applications. With unique products such as Black Diamond Infrared Lenses and Gradium Lenses, LightPath Technologies is shedding light in the field of optical solutions. For further information, visit the company website at: www.lightpath.com.
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company, is committed to developing and commercializing innovative small molecule drugs for the treatment of cancer. Pralatrexate (PDX), the Company's lead product candidate, is a novel antifolate currently in a pivotal Phase 2 (PROPEL) trial. RH1, a targeted chemotherapeutic agent, is Allos Therapeutics’ other product candidate and is currently being evaluated in a Phase 1 trial. For further information, visit the Company's web site at www.allos.com.
LCA-Vision, Inc. (NASDAQ: LCAV) provides laser vision correction services under its well known Lasik Plus brand. The company currently owns and operates over 70 LasikPlus fixed-site laser vision correction centers in the United States and a joint venture in Canada. These laser correction centers are staffed with experienced ophthalmologists, optometrists and other healthcare professionals. To date, the company has performed more than a million vision correction procedures. For further information, visit the Company's web site at www.lcavision.com.
Alhambra Resources Ltd. (TSX: ALH CN), a Canadian based exploration and gold production corporation, operates through its wholly owned subsidiary, Saga Creek Gold Corp LLP ("Saga Creek"). The company holds the rights to two Licenses that have an initial term of 25 years granted by the Republic of Kazakhstan in 1997. These two Licenses are the subject of an exploration and exploitation Contract between Saga Creek and the Republic of Kazakhstan, and will not expire until the year 2022. For further information, visit the Company's web site at www.alhambraresources.com.
LAURION Mineral Exploration Inc. (TSX: LME CN), an exploration company, has its focus on discovering multiple, high-impact project, from gold projects to base metals and PGE’s. The company has key interests in highly prospective properties and aims to achieve long-term growth by making sound business decisions, creating strategic alliances with companies that have high technical expertise, and strategically target well positioned projects in geological systems where discoveries have been repetitive. For further information, visit the Company's web site at www.laurion.ca.
Alberta Oilsands Inc. (TSX: AOS CN), a junior oil sands development company, is focusing their operations on the Athabasca oil sands region of northeast Alberta. The company intends to create long term, sustainable value through the rapid delineation of the oil sands resources. Alberta’s strategy is to leverage its proven oil sands experience to delineate and prove up bitumen reserves sufficient to support a minimum 10,000 barrel per day in-situ project within five years. For further information, visit the Company's web site at www.aboilsands.ca.
Lake Shore Gold Corp. (TSX: LSG CN), a mineral exploration company, is focused on rapidly moving towards production through a portfolio which includes an existing processing facility and a number of quality mineral properties located in the Timmins gold mining district of northern Ontario and Québec. In just the past year, Lake Shore Gold has completed a pre-feasibility study, identified a 1.2 million ounce ore reserve (uncut) and commenced an advanced exploration program at its 100%-owned Timmins West project. For further information, visit the Company's web site at www.lsgold.com
Labrador Iron Mines Holdings Limited (TSX: LIR CN) has acquired interests in mineral claims and mineral licenses, through its wholly owned subsidiary, that contain an estimated 100 million tons of high grade iron ore. The company’s management team is comprised of experienced mining professionals, each of which has at least 30 years experience in the resource industry covering exploration, development, operations, company and project financing. For further information, visit the Company's web site at www.labradorironmines.ca.
Akesis Pharmaceuticals, Inc.’s (OTC BB: AKES) focus is on the treatment of diabetes and related metabolic disorders. They have a pipeline of innovative oral product candidates that are supported by issued and filed U.S. patents. Their product candidates are proven to lower and control blood glucose levels in patients with Type 2 diabetes. With approximately 20 million people suffering from diabetes in the U.S. alone, blood sugar control via oral drugs represents a multi-billion dollar market opportunity. For further information, visit the Company's web site at www.akesis.com.
La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on improving and preserving human life through the development of novel pharmaceutical products. Riquent®, the company's leading product in development, treats lupus renal disease, a leading cause of sickness and death in patients with lupus, by preventing or delaying renal flares. Additionally, La Jolla has developed small molecules designed to treat other autoimmune and inflammatory conditions. For further information, visit the Company's web site at www.ljpc.com.
